HLB TherapeuticsHLB테라퓨틱스
115450 · KOSDAQ · ₩115450 · HLB테라퓨틱스
₩2,635▼ ₩15 (0.57%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩70B | ₩55B | ₩54B | ₩48B | ₩44B |
| Cost of sales | ₩59B | ₩45B | ₩46B | ₩39B | ₩38B |
| Gross profit | ₩10B | ₩10B | ₩7.5B | ₩9.3B | ₩5.1B |
| Operating income | −₩3.5B | −₩7.6B | −₩8.7B | −₩7.9B | −₩11B |
| Net income | −₩9.7B | −₩23B | −₩3.1B | −₩12B | −₩18B |
| Net income to shareholders | −₩9.2B | −₩23B | −₩2.3B | −₩11B | −₩17B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩229B | ₩220B | ₩201B | ₩188B | ₩190B |
| Current assets | ₩75B | ₩54B | ₩50B | ₩80B | ₩113B |
| Cash and equivalents | ₩20B | ₩18B | ₩24B | ₩46B | ₩100B |
| Total liabilities | ₩55B | ₩38B | ₩29B | ₩60B | ₩60B |
| Current liabilities | ₩26B | ₩32B | ₩27B | ₩59B | ₩57B |
| Borrowings | ₩36B | ₩23B | ₩9.3B | ₩52B | ₩50B |
| Total equity | ₩174B | ₩182B | ₩172B | ₩128B | ₩130B |
| Shareholders' equity | ₩150B | ₩157B | ₩160B | ₩117B | ₩119B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩8.2B | ₩1.3B | ₩3.3B | −₩8.8B | −₩11B |
| Capital spending | ₩1.3B | ₩636M | ₩302M | ₩3.4B | ₩823M |
| Free cash flow | −₩9.5B | ₩652M | ₩3B | −₩12B | −₩12B |
| Dividends paid | — | — | — | — | ₩0 |
Consolidated where available. Amounts in won.
Also known as: HLB Therapeutics / HLB테라퓨틱스 / 115450 / KRX:115450
Source: KRX statistical information